title: Effects of dendroaspis natriuretic peptide on calcium-activated potassium current and its mechanism.
abstract: In this study, we sought to investigate the effect of dendroaspis natriuretic peptide (DNP) on calcium-activated potassium current (I K(Ca)) and its mechanism in gastric antral circular smooth muscle cells (SMCs) using the whole-cell patch-clamp technique. DNP concentration-dependently increased macroscopic I K(Ca) and spontaneous transient outward currents (STOCs) in freshly isolated guinea pig gastric antral circular SMCs. The effects of DNP on I K(Ca) and/or STOCs were not blocked by applying calcium-free bath solution or the ryanodine receptor (RyR) antagonist ryanodine (10 microM), but they were inhibited by the inositol triphosphate receptor (IP3R) inhibitor heparin or the guanylate cyclase inhibitor LY83583. Moreover, a DNP-induced increase in STOCs was potentiated by the cyclic guanosine monophosphate (cGMP)-sensitive phosphoesterase inhibitor zaprinast. In conclusion, our results suggest that DNP increases I K(Ca) in gastric antral circular SMCs by increasing cGMP production and activating IP3Rs.
authors: Central Laboratory, First Affiliated Hospital of Dalian Medical Universty, Dalian, China. guohuishu1@yahoo.com.cn
authors: Hui-Shu
authors: HS
authors: Guo
authors: Yan-Zong
authors: YZ
authors: Yang
authors: Yuan
authors: Y
authors: Zou
authors: Jing
authors: J
authors: Xu
authors: Zheng-Xu
authors: ZX
authors: Cai
authors: Qing-Hui
authors: QH
authors: Qi
mesh_terms: D000634:Aminoquinolines / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004546:Elapid Venoms / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006168:Guinea Pigs; D053496:Inositol 1,4,5-Trisphosphate Receptors / Q000502:physiology; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D009119:Muscle Contraction / Q000187:drug effects* / Q000502:physiology; D009130:Muscle, Smooth / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000502:physiology; D009529:Nicardipine / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D024681:Potassium Channels, Calcium-Activated / Q000502:physiology*; D011688:Purinones / Q000494:pharmacology; D011706:Pyloric Antrum / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D012433:Ryanodine / Q000494:pharmacology; D019837:Ryanodine Receptor Calcium Release Channel / Q000502:physiology
chemical_list: D000634:Aminoquinolines; D002121:Calcium Channel Blockers; C075597:Dendroaspis natriuretic peptide; D004546:Elapid Venoms; D004791:Enzyme Inhibitors; D053496:Inositol 1,4,5-Trisphosphate Receptors; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D010726:Phosphodiesterase Inhibitors; D024681:Potassium Channels, Calcium-Activated; D011688:Purinones; D019837:Ryanodine Receptor Calcium Release Channel; D012433:Ryanodine; C041715:6-anilino-5,8-quinolinedione; D009529:Nicardipine; C011145:zaprinast; D002118:Calcium